https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Ayala_Pharmaceuticals%2C_Inc.Ayala Pharmaceuticals, Inc. - Revizia istoricului2026-04-10T03:37:40ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Ayala_Pharmaceuticals,_Inc.&diff=408485&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Ayala Pharmaceuticals, Inc. listata cu simbolul US.AYLA ==Descriere companie== Ayala Pharmaceuticals, Inc. (www.ayalapharma.com) is a clinical-stage oncology company. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers. The Company's portfolio of product candidates includes, AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibi...2024-09-18T13:40:55Z<p>Pagină nouă: Pagina dedicata companiei Ayala Pharmaceuticals, Inc. listata cu simbolul US.AYLA ==Descriere companie== Ayala Pharmaceuticals, Inc. (www.ayalapharma.com) is a clinical-stage oncology company. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers. The Company's portfolio of product candidates includes, AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibi...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Ayala Pharmaceuticals, Inc. listata cu simbolul US.AYLA<br />
<br />
==Descriere companie==<br />
Ayala Pharmaceuticals, Inc. (www.ayalapharma.com) is a clinical-stage oncology company. The Company is focused on developing and commercializing small molecule therapeutics for patients suffering from rare cancers. The Company's portfolio of product candidates includes, AL101 and AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidates AL101 and AL102, are developed as potent, selective, small molecule gamma secretase inhibitors (GSIs). The Company is evaluating AL101 as a monotherapy in an open-label Phase II clinical trial for the treatment of patients with Notch-activated recurrent/metastatic triple negative breast cancer (R/M TNBC). It is developing AL101 for the treatment of T-ALL, a rare form of T-cell specific leukemia. It is evaluating AL102 as a monotherapy in a Phase II / III pivotal study (RINGSIDE) for the treatment of desmoid tumors in adult and adolescent patients.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.AYLA" /><br />
<br />
==Ultimele stiri despre Ayala Pharmaceuticals, Inc. (US.AYLA)==<br />
<dynamicpagelist><br />
category=US.AYLA<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.AYLA]][[Categorie:Stiri despre companii]]</div>Admin